Kateryna Shostak 1 , 2 , 3 , Xin Zhang 1 , 2 , 3 , Pascale Hubert 1 , 4 , 5 , Serkan Ismail Göktuna 1 , 2 , 3 , Zheshen Jiang 1 , 2 , 3 , Iva Klevernic 1 , 2 , 3 , Julien Hildebrand 1 , 2 , 3 , Patrick Roncarati 1 , 4 , 5 , Benoit Hennuy 1 , 6 , Aurélie Ladang 1 , 2 , 3 , Joan Somja 1 , 4 , 5 , André Gothot 1 , 7 , Pierre Close 1 , 2 , 3 , Philippe Delvenne 1 , 4 , 5 , Alain Chariot a , 1 , 2 , 3 , 8
04 November 2014
Constitutive activation of EGFR- and NF-κB-dependent pathways is a hallmark of cancer, yet signalling proteins that connect both oncogenic cascades are poorly characterized. Here we define KIAA1199 as a BCL-3- and p65-dependent gene in transformed keratinocytes. KIAA1199 expression is enhanced on human papillomavirus (HPV) infection and is aberrantly expressed in clinical cases of cervical (pre)neoplastic lesions. Mechanistically, KIAA1199 binds Plexin A2 and protects from Semaphorin 3A-mediated cell death by promoting EGFR stability and signalling. Moreover, KIAA1199 is an EGFR-binding protein and KIAA1199 deficiency impairs EGF-dependent Src, MEK1 and ERK1/2 phosphorylations. Therefore, EGFR stability and signalling to downstream kinases requires KIAA1199. As such, KIAA1199 promotes EGF-mediated epithelial–mesenchymal transition (EMT). Taken together, our data define KIAA1199 as an oncogenic protein induced by HPV infection and constitutive NF-κB activity that transmits pro-survival and invasive signals through EGFR signalling.
The cross-talk between constitutively active EGFR- and NF-κB-dependent pathways in cancer is poorly understood. Here, the authors identify KIAA1199 as a BCL3 and NF-κB-regulated protein that is expressed in cervical lesions and promotes tumorigenesis through Plexin A2 binding and regulation of EGFR stability.